ChemoCentryx, Inc. (CCXI): Price and Financial Metrics


ChemoCentryx, Inc. (CCXI): $34.06

-0.51 (-1.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CCXI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 509

in industry

CCXI POWR Grades


  • CCXI scores best on the Sentiment dimension, with a Sentiment rank ahead of 60.93% of US stocks.
  • The strongest trend for CCXI is in Momentum, which has been heading down over the past 52 weeks.
  • CCXI's current lowest rank is in the Stability metric (where it is better than 2.12% of US stocks).

CCXI Stock Summary

  • With a price/sales ratio of 113.25, ChemoCentryx Inc has a higher such ratio than 96.92% of stocks in our set.
  • As for revenue growth, note that CCXI's revenue has grown -71.6% over the past 12 months; that beats the revenue growth of just 2.71% of US companies in our set.
  • The volatility of ChemoCentryx Inc's share price is greater than that of 99.32% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to CCXI, based on their financial statements, market capitalization, and price volatility, are MNOV, HRTX, RESN, ACRS, and FREQ.
  • CCXI's SEC filings can be seen here. And to visit ChemoCentryx Inc's official web site, go to www.chemocentryx.com.

CCXI Valuation Summary

  • CCXI's EV/EBIT ratio is -9.1; this is 131.06% lower than that of the median Healthcare stock.
  • CCXI's price/sales ratio has moved up 40 over the prior 116 months.
  • CCXI's price/earnings ratio has moved up 116.3 over the prior 116 months.

Below are key valuation metrics over time for CCXI.

Stock Date P/S P/B P/E EV/EBIT
CCXI 2021-08-31 51.1 3.3 -9.0 -9.1
CCXI 2021-08-30 49.9 3.3 -8.8 -8.9
CCXI 2021-08-27 50.9 3.3 -9.0 -9.1
CCXI 2021-08-26 50.0 3.3 -8.8 -8.9
CCXI 2021-08-25 49.0 3.2 -8.6 -8.8
CCXI 2021-08-24 48.1 3.1 -8.5 -8.6

CCXI Growth Metrics

  • Its 4 year cash and equivalents growth rate is now at 342.89%.
  • The 4 year net income to common stockholders growth rate now stands at -29.06%.
  • Its 4 year price growth rate is now at 1770.9%.
CCXI's revenue has moved up $21,609,000 over the prior 67 months.

The table below shows CCXI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 21.609 -74.797 -122.856
2021-03-31 69.236 -75.264 -63.38
2020-12-31 64.891 -81.143 -55.356
2020-09-30 70.58 -82.149 -41.008
2020-06-30 76.076 -82.726 -29.81
2020-03-31 33.809 -79.283 -65.227

CCXI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CCXI has a Quality Grade of D, ranking ahead of 10.28% of graded US stocks.
  • CCXI's asset turnover comes in at 0.043 -- ranking 332nd of 681 Pharmaceutical Products stocks.
  • BHC, LUMO, and CBAY are the stocks whose asset turnover ratios are most correlated with CCXI.

The table below shows CCXI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.043 1 -0.262
2021-03-31 0.132 1 -0.148
2020-12-31 0.145 1 -0.163
2020-09-30 0.191 1 -0.166
2020-06-30 0.262 1 -0.190
2020-03-31 0.159 1 -0.476

CCXI Price Target

For more insight on analysts targets of CCXI, see our CCXI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.50 Average Broker Recommendation 1.31 (Strong Buy)

CCXI Stock Price Chart Interactive Chart >

Price chart for CCXI

CCXI Price/Volume Stats

Current price $34.06 52-week high $70.29
Prev. close $34.57 52-week low $9.53
Day low $34.06 Volume 10,380
Day high $34.06 Avg. volume 3,081,080
50-day MA $21.05 Dividend yield N/A
200-day MA $32.42 Market Cap 2.38B

ChemoCentryx, Inc. (CCXI) Company Bio


ChemoCentryx, Inc. focuses on the discovery, development, and commercialization of orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. The company was founded in 1997 and is based in Mountain View, California.


CCXI Latest News Stream


Event/Time News Detail
Loading, please wait...

CCXI Latest Social Stream


Loading social stream, please wait...

View Full CCXI Social Stream

Latest CCXI News From Around the Web

Below are the latest news stories about ChemoCentryx Inc that investors may wish to consider to help them evaluate CCXI as an investment opportunity.

ChemoCentryx Stock: Worth Keeping an Eye on

I am neutral on ChemoCentryx (CCXI) because the upside potential embedded in its development pipeline is offset by the speculative nature of the business, and its lack of profitability at present. ChemoCentryx is a biopharmaceutical corporation that manufactures and markets innovative orally administered therapeutic medication for autoimmune and inflammatory diseases and cancers. (See Insiders’ Hot Stocks on TipRanks) Strengths ChemoCentryx’s lead drug candidate, Avacopan (CCX168), has successfully completed its ANCA-associated vasculitis Phase 3 trial, and has entered its late-stage clinical development to treat severe cases of Hidradenitis Suppurativa and C3G (C3 glomerulopathy).

Samuel Smith on TipRanks | October 15, 2021

Is It Too Late to Buy ChemoCentryx Stock?

The U.S. Food and Drug Administration (FDA) granted approval for the company's autoimmune drug, avacopan, which instantly led to shares of ChemoCentryx more than doubling in value. For investors who didn't want to take on the risk heading into the FDA decision, the obvious question now is whether it's too late to invest in the healthcare stock. After amassing such impressive returns over a short time frame, can investors who buy the stock today still expect to earn a good return on their investment?

Yahoo | October 14, 2021

2 Super-Charged Growth Stocks to Buy Now

Growth stocks can be a thing of beauty. The trick, if you will, is to suss out growth stocks that won't rot on the vine, so to speak. While both of these biotech stocks have more than doubled in value in the past three years, I believe each of these healthcare equities still has a lot of room to run in 2022 and beyond.

Yahoo | October 13, 2021

Keep on Buying Chemocentryx Stock, Says Analyst Following FDA Approval

The risk that a drug in development might fail to meet its targets or satisfy the regulators’ assessment is one investors of biotech companies always need to consider. But if the drug impresses in testing and cuts the mustard in the regulators’ eyes, then the rewards are like in no other segment of the stock market. Chemocentryx (CCXI) is a good example here; in Friday’s session, shares almost doubled after the biotech’s treatment of a rare autoimmune disease received the FDA’s seal of approval.

Marty Shtrubel on TipRanks | October 11, 2021

3 ‘Strong Buy’ Stocks Raymond James Predicts Will Rally Over 60%

As Q4 gets into full swing, we can take a moment to look back over our shoulders at where we’ve come from. The sustained upward trend of the markets is obvious from this view, and the recent downturn in the market appears as a bump against some otherwise solid gains. Even so, there are reasons for concern right now. The COVID pandemic hasn’t gone away – and it doesn’t look like it will go away either. The September jobs numbers were weak, and unemployment only fell because too many people left the workforce.

Michael Marcus on TipRanks | October 11, 2021

Read More 'CCXI' Stories Here

CCXI Price Returns

1-mo 87.14%
3-mo 132.33%
6-mo -25.96%
1-year -42.07%
3-year 210.77%
5-year 449.35%
YTD -44.99%
2020 56.56%
2019 262.51%
2018 83.36%
2017 -19.59%
2016 -8.64%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8176 seconds.